CD4 immunoadhesin is a recombinant fusion protein consisting of a combination of CD4 and the fragment crystallizable region, similarly known as immunoglobulin. It belongs to the antibody (Ig) gene family. CD4 is a surface receptor for human immunodeficiency virus (HIV). The CD4 immunoadhesin molecular fusion allow the protein to possess key functions from each independent subunit. The CD4 specific properties include the gp120-binding and HIV-blocking capabilities. Properties specific to immunoglobulin are the long plasma half-life and Fc receptor binding. The properties of the protein means that it has potential to be used in AIDS therapy as of 2017. Specifically, CD4 immunoadhesin plays a role in antibody-dependent cell-mediated cytotoxicity (ADCC) towards HIV-infected cells. While natural anti-gp120 antibodies exhibit a response towards uninfected CD4-expressing cells that have a soluble gp120 bound to the CD4 on the cell surface, CD4 immunoadhesin, however, will not exhibit a response. One of the most relevant of these possibilities is its ability to cross the placenta.
History and significance
CD4 immunoadhesin was first developed in the mid-1990s as a potential therapeutic agent and treatment for HIV/AIDS. The protein is a fusion of the extracellular domain of the CD4 receptor and the Fc domain of human immunoglobulin G (IgG), the most abundant antibody isotype in the human body. The Fc domain of IgG contributes several important properties to the fusion protein, including increased half-life in the bloodstream, enhanced binding to Fc receptors on immune cells, and the ability to activate complement.
The development of CD4 immunoadhesin stems from the observation that the CD4 receptor plays a critical role in the entry of HIV into human cells. The CD4 receptor is used as a primary receptor by HIV to attach to the surface of target cells. HIV then uses a co-receptor, either CCR5 or CXCR4, to facilitate entry into the cell. The ability of CD4 immunoadhesin to block the interaction between the CD4 receptor and HIV was intended to prevent HIV from entering and infecting human cells.
CD4 immunoadhesin has been extensively studied in preclinical and clinical trials as a potential treatment for HIV/AIDS. In addition to its antiviral activity, CD4 immunoadhesin has also been investigated for its potential immunomodulatory effects. For example, the fusion protein has been shown to induce the production of cytokines, such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ), which are important for the activation and proliferation of immune cells.
Despite its potential as a therapeutic agent, the development of CD4 immunoadhesin has faced several challenges. One major obstacle is the emergence of drug-resistant strains of HIV, which can limit the effectiveness of CD4 immunoadhesin in certain patients. Additionally, the need for frequent dosing and the potential for immune responses against the fusion protein have also limited the clinical application of CD4 immunoadhesin.
Nevertheless, knowledge on the function of CD4 immunoadhesin has contributed to increased understanding of the biology of HIV and the mechanisms of viral entry. The protein has also inspired the development of other immunoadhesin molecules, such as CD4-IgG2 and CD4-mimetic compounds, which are being investigated as potential therapies for HIV/AIDS.
Structure and function
CD4 immunoadhesin is a bifunctional protein that has the ability to block HIV infection, inhibit autoreactive T-cell activation, and potentially modulate immune responses. Its structure, which consists of the extracellular domain of CD4 and the Fc region of IgG1, allows for soluble circulation throughout the body.
The extracellular domain of CD4 contains four immunoglobulin-like domains (D1-D4), which are responsible for binding to the major histocompatibility complex (MHC) class II molecules on antigen-presenting cells. The Fc region of IgG1 is responsible for mediating effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement activation.
CD4-Ig works by mimicking the binding of CD4 to HIV, thereby preventing the virus from infecting T-helper cells. HIV infects T-helper cells by binding to the CD4 receptor and the co-receptor CCR5 or CXCR4. CD4-Ig binds to the viral envelope glycoprotein gp120, which is responsible for HIV binding to CD4. By binding to gp120, CD4-Ig prevents the virus from binding to the CD4 receptor on T-helper cells, thus preventing infection.